Klinische Forschung Berlin GbR

At Klinische Forschung Berlin GbR, investigators are exploring new strategies to improve outcomes for patients with heart failure and related cardiovascular risk factors.

• Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
• Hypercholesterolemia management with novel LDL‑C lowering agents
• Evaluation of anti‑inflammatory biologic therapy to reduce cardiovascular death and heart‑failure events

The site’s multidisciplinary team collaborates closely with cardiology specialists to bring innovative treatments to the clinic.

Research focuses on protecting healthy volunteers and at‑risk populations from influenza complications through vaccine immunogenicity and novel oral delivery systems.

• Immunogenicity comparison of high‑dose quadrivalent influenza vaccine in adults 50+ years
• Assessment of safety and antibody response using cell‑derived virus assays
• Evaluation of placebo‑controlled efficacy of nicotine mouthspray for e‑cigarette cessation, reducing respiratory viral risk

The Berlin site leverages its experience in infectious disease trials to support public‑health vaccination programs.

Trials address lifestyle‑related conditions such as vaping cessation and metabolic disturbances, aiming to improve cessation rates and lipid profiles.

• Nicotine Freshmint Mouthspray effectiveness for e‑cigarette users seeking quit
• Novel oral peptide inhibitor MK‑0616 to lower LDL‑C in hypercholesterolemic participants
• Safety monitoring of investigational agents in stable comorbid populations

Klinische Forschung Berlin’s commitment to patient‑centered research ensures rigorous evaluation of emerging therapies.